News
EMA accepts filing for Biogen/Samsung Bioepis’ Lucentis biosimilar
The European Medicines Agency (EMA) has accepted for review the marketing authorisation for Biogen and Samsung Bioepis’ biosimilar referencing Genentech’s Lucentis (ranibizumab).